Leuko is developing PointCheck™, the first device for non-invasive white cell monitoring. PointCheck™ is fast, portable and simple to use. By removing the need for a blood draw, millions of immunosuppressed patients can now be tested more frequently, moving towards improved quality of life and improved clinical outcomes.